M Bocchia

Summary

Affiliation: University of Siena
Country: Italy

Publications

  1. ncbi request reprint Emerging drugs in chronic myelogenous leukaemia
    Monica Bocchia
    Universita di Siena, Sezione di Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze Immunologiche, AOUS, Viale Bracci 53100 Siena, Italy
    Expert Opin Emerg Drugs 11:651-64. 2006
  2. doi request reprint Peptide vaccines for hematological malignancies: a missed promise?
    Monica Bocchia
    Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100, Siena, Italy
    Int J Hematol 99:107-16. 2014
  3. doi request reprint Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination
    Monica Bocchia
    Hematology and Transplants, University of Siena and AOUS, Viale Bracci 16, 53100 Siena, Italy
    Nat Rev Clin Oncol 7:600-3. 2010
  4. ncbi request reprint Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial
    M Bocchia
    Department of Haematology, Siena University, Siena, Italy
    Lancet 365:657-62. 2005
  5. ncbi request reprint Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas
    M Bocchia
    Cattedra e Divisione di Ematologia, Ospedale Sclavo, via Tufi, 1, 53100 Siena, Italy
    Haematologica 84:716-20. 1999
  6. ncbi request reprint Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients
    D Laszlo
    Department of Hematology, University of Siena, Italy
    Leuk Lymphoma 37:157-61. 2000
  7. doi request reprint Unusual discordant responses in two multiple myeloma patients during bortezomib treatment
    Maria Teresa Pirrotta
    Division of Hematology and Transplants, University of Siena, Policlinico Santa aria alle Scotte, Siena, Italy
    Onkologie 31:45-7. 2008
  8. ncbi request reprint Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications
    F Lauria
    Department of Hematology, University of Siena, Italy
    Haematologica 84:22-5. 1999
  9. ncbi request reprint CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland
    F Forconi
    Cattedra e Divisione di Ematologia, Ospedale Sclavo, Via Tufi 1, 53100 Siena, Italy
    Haematologica 84:946-8. 1999
  10. ncbi request reprint Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
    G Marotta
    Department of Hematology, A Sclavo Hospital, via Tufi, 1 53100 Siena, Italy
    Haematologica 85:1268-70. 2000

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Emerging drugs in chronic myelogenous leukaemia
    Monica Bocchia
    Universita di Siena, Sezione di Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze Immunologiche, AOUS, Viale Bracci 53100 Siena, Italy
    Expert Opin Emerg Drugs 11:651-64. 2006
    ..Furthermore, additive immunotherapeutic strategies are emerging to synergise with imatinib in the elimination of molecular residual disease. This paper reviews the current details regarding these approaches and their developments...
  2. doi request reprint Peptide vaccines for hematological malignancies: a missed promise?
    Monica Bocchia
    Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Viale Bracci 16, 53100, Siena, Italy
    Int J Hematol 99:107-16. 2014
    ....
  3. doi request reprint Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination
    Monica Bocchia
    Hematology and Transplants, University of Siena and AOUS, Viale Bracci 16, 53100 Siena, Italy
    Nat Rev Clin Oncol 7:600-3. 2010
    ..Disease remained at molecular level...
  4. ncbi request reprint Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial
    M Bocchia
    Department of Haematology, Siena University, Siena, Italy
    Lancet 365:657-62. 2005
    ..We investigated whether a vaccine targeting the BCR-ABL-derived p210 fusion protein was an active and specific immunotherapy...
  5. ncbi request reprint Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas
    M Bocchia
    Cattedra e Divisione di Ematologia, Ospedale Sclavo, via Tufi, 1, 53100 Siena, Italy
    Haematologica 84:716-20. 1999
    ..The aim of this study was to evaluate a strategy aimed at lowering therapy-related toxic effects without affecting the reported good response rate...
  6. ncbi request reprint Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients
    D Laszlo
    Department of Hematology, University of Siena, Italy
    Leuk Lymphoma 37:157-61. 2000
    ....
  7. doi request reprint Unusual discordant responses in two multiple myeloma patients during bortezomib treatment
    Maria Teresa Pirrotta
    Division of Hematology and Transplants, University of Siena, Policlinico Santa aria alle Scotte, Siena, Italy
    Onkologie 31:45-7. 2008
    ..Cases of discordant responses in multiple myeloma (MM) patients after thalidomide therapy have been sometimes reported, in which extramedullary masses progress or present de novo with a simultaneous serum monoclonal protein reduction...
  8. ncbi request reprint Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications
    F Lauria
    Department of Hematology, University of Siena, Italy
    Haematologica 84:22-5. 1999
    ..In the present study we report response rate and toxicity of weekly 2CdA administration in a larger cohort of patients and with a longer follow-up...
  9. ncbi request reprint CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland
    F Forconi
    Cattedra e Divisione di Ematologia, Ospedale Sclavo, Via Tufi 1, 53100 Siena, Italy
    Haematologica 84:946-8. 1999
    ..We report a case of CD30-positive non-anaplastic (ALK1-negative) peripheral T cell lymphoma of the thyroid gland and speculate on aspects concerning diagnosis and the morphologic and immunohistochemical findings...
  10. ncbi request reprint Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
    G Marotta
    Department of Hematology, A Sclavo Hospital, via Tufi, 1 53100 Siena, Italy
    Haematologica 85:1268-70. 2000
    ....
  11. pmc Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Enterococcus faecium
    S Sammassimo
    Department of Hematology and Hematopoietic Stem Cell Transplantation, University of Siena, Siena, Italy
    J Clin Microbiol 42:487-9. 2004
    ..The presentation was unusual because the early symptoms were fever and pain, and the disease was misdiagnosed because of a concomitant infection by Enterococcus faecium...
  12. ncbi request reprint Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib
    Alessandro Gozzetti
    Division of Hematology and Transplants, Policlinico Santa Maria alle Scotte, University of Siena, Italy
    Clin Lymphoma Myeloma 7:376-8. 2007
    ....
  13. doi request reprint Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma
    Alessandro Gozzetti
    Division of Hematology and Transplants, University of Siena, Italy
    Clin Lymphoma Myeloma Leuk 10:68-72. 2010
    ..The synergic, additive effect of bortezomib and pegylated liposomal doxorubicin (PLD) has never been tested in an elderly group of patients with relapsed/refractory multiple myeloma (MM)...
  14. ncbi request reprint A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate
    Alessandro Gozzetti
    Division of Hematology and Transplants, Department of Medicine and Immunological Sciences, University of Siena, Policlinico Le Scotte, 53100 Siena, Italy
    Cancer Genet Cytogenet 148:152-4. 2004
    ....
  15. ncbi request reprint Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
    F Lauria
    Department of Hematology A Sclavo Hospital, Via Tufi 1, 53100 Siena, Italy
    Haematologica 86:1046-50. 2001
    ..Based on these premises we evaluated the efficacy and the toxicity of chimeric anti-CD20 monoclonal antibody (MoAb) in relapsed/progressed hairy cell leukemia (HCL)...
  16. ncbi request reprint Myeloid sarcoma and adenocarcinoma of the large bowel as collision tumors: a case report
    B J Rocca
    Department of Human Pathology and Oncology, Anatomic Pathology Section, University of Siena, Italy
    Histol Histopathol 27:941-7. 2012
    ..Since only one case report has evaluated the correlation between myeloid sarcoma and adenocarcinoma of the large bowel, further immunohistochemical and molecular studies are needed to clarify the pathogenetic relationship between them...
  17. ncbi request reprint Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients
    Maria Teresa Pirrotta
    Department of Hematology, University of Siena, Siena, Italy
    Acta Haematol 118:7-9. 2007
  18. ncbi request reprint Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
    Michele Malagola
    Blood 105:904; author reply 905. 2005
  19. ncbi request reprint Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment
    Alessandro Gozzetti
    Acta Haematol 117:236-7. 2007
  20. ncbi request reprint Concomitant t(4;11) and t(1;19) in a patient with biphenotypic acute leukemia
    Alessandro Gozzetti
    Cancer Genet Cytogenet 177:81-2. 2007
  21. ncbi request reprint Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI)
    Alessandro Gozzetti
    Eur J Haematol 71:313-4. 2003
  22. ncbi request reprint Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different clonal origin shown by molecular cytogenetics
    Alessandro Gozzetti
    Cancer Genet Cytogenet 180:83-4. 2008
  23. doi request reprint Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases
    Michele Malagola
    Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Eur J Haematol 81:354-63. 2008
    ..The intensification of induction chemotherapy and the use of non-conventional drugs such as fludarabine are considered responsible for the increased risk of infections...
  24. ncbi request reprint Insights into JAK2-V617F mutation in CML
    Monica Bocchia
    Lancet Oncol 8:864-6. 2007
  25. ncbi request reprint Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
    Michele Malagola
    Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Br J Haematol 136:87-95. 2007
    ..In this setting of patients, large prospective randomised studies should be planned...
  26. ncbi request reprint Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission
    Alessandro Gozzetti
    Cancer Genet Cytogenet 167:182. 2006
  27. ncbi request reprint Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis
    Serena Mazzotta
    Department of Medicine and Immunological Sciences, Division of Hematology and Transplants, University of Siena, Italy
    Leuk Lymphoma 46:1837-8. 2005
    ..A brief review of the literature and suggestions for possible predictive factors of this toxicity are made...
  28. ncbi request reprint Is there any role left for p210-derived peptide vaccines in chronic myeloid leukemia?
    Monica Bocchia
    Haematologica 87:675-7. 2002
  29. ncbi request reprint Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia
    Maria Teresa Pirrotta
    Leuk Lymphoma 46:793. 2005
  30. ncbi request reprint Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma
    Maria Teresa Pirrotta
    Oncologist 10:299-300. 2005
  31. ncbi request reprint Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC)
    Monica Bocchia
    Haematologica 88:358-60. 2003
  32. ncbi request reprint A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia
    Alessandro Gozzetti
    Cancer Genet Cytogenet 154:193-4. 2004
  33. ncbi request reprint Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Domenico Russo
    Unit of Blood Diseases and Cell Therapy, Brescia University, Brescia, Italy
    Br J Haematol 131:172-9. 2005
    ..Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients...